Does MRI-derived Wall Thickness Standard Deviation (WTSD) accurately detect overt and early sarcomeric HCM in mutation carriers?
MRI-derived wall thickness heterogeneity (WTSD) may serve as a highly accurate imaging biomarker for the early identification of hypertrophic cardiomyopathy, particularly in women and mutation carriers.
WTSD is a robust imaging biomarker that detects both overt and early sarcomeric HCM with high accuracy. Incorporating WT heterogeneity into diagnostic algorithms may enhance early identification, especially in women and mutation carriers.
Aquaro et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: